Navigation Links
Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find
Date:4/20/2011

DALLAS April 21, 2011 Even people who show a clear treatment response with antidepressant medications continue to experience symptoms like insomnia, sadness and decreased concentration, researchers at UT Southwestern Medical Center have found after analyzing data from the largest study on the treatment of depression.

"Widely used antidepressant medications, while working overall, missed these symptoms. If patients have persistent residual symptoms, these individuals have a high probability of incomplete recovery," said Dr. Shawn McClintock, assistant professor of psychiatry and lead author of the analysis available in the April print issue of the Journal of Clinical Psychopharmacology.

UT Southwestern researchers tracked a wide range of symptoms of depression including sadness, suicidal thoughts, and changes in sleep patterns, appetite/weight, concentration, outlook and energy/fatigue at the start of the trial and at the end of the antidepressant treatment course.

Dr. McClintock's research used data from the Sequenced Treatment Alternatives to Relieve Depression, or STAR*D study, the largest ever on the treatment of major depressive disorder and considered a benchmark in the field of depression research. The six-year, National Institute of Mental Health-sponsored study initially included more than 4,000 patients with major depressive disorder from clinics across the country. Dr. Madhukar Trivedi, professor of psychiatry at UT Southwestern, was co-principal investigator of STAR*D and an author on this paper that analyzed data.

All responders reported between three to 13 residual depressive symptoms, and 75 percent of participants reported five symptoms or more.

Some of their symptoms included insomnia that occurs in the middle of the night (nearly 79 percent); sadness (nearly 71 percent); and decreased concentration and decision-making skills (nearly 70 percent). Moderately severe midnoctural insomnia was reported in nearly 60 percent of participants more than twice as frequently as other symptoms.

Thoughts of suicide rarely persisted or emerged during treatment, researchers found.

"Some people fear that antidepressant medication increases thoughts of suicide," Dr. McClintock said. "This provided counterevidence of that."

Researchers in the STAR*D trial found that only 33 percent of people go into remission in the first 12 weeks of treatment with an antidepressant medication known as an SSRI, or selective serotonin reuptake inhibitor. Of the available antidepressant medications, SSRIs are the most commonly prescribed for the treatment of depression.

Individuals on SSRIs often still exhibit symptoms of depression. For one of first times, researchers sought with this analysis in a large sample to identify residual symptoms of the disease and whether these symptoms began before or during treatment.

Dr. McClintock and colleagues looked at data from the 2,876 STAR*D participants who completed the first phase of the trial treatment with an SSRI for 12 weeks. About 15 percent of those participants, or 428 people, responded to treatment with no remission. Response was defined as a 50 percent decrease in severity of depression. The average age of participants was 40, 73 percent were white, and 66 percent were female.

Each year about 19 million adults in America struggle with depression. People with depression are often at increased risk of heart disease, diabetes, asthma and obesity. Depression cost the U.S. an estimated $83 billion a year.

The next step, Dr. McClintock said, will be to develop more targeted antidepressant therapies to decrease depressive symptoms, and to understand better the association between depression and concentration.

Dr. Trivedi said, "Our findings do suggest that the use of measurement-based care techniques to identify and target residual depressive symptoms is essential to help patients return to normal function and recover from depression in the long term."


'/>"/>

Contact: LaKisha Ladson
lakisha.ladson@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. U. Iowa study suggests antidepressants aid physical recovery in stroke
2. Study Hints at Link Between Antidepressants and Heart Trouble
3. Antidepressants linked to thicker arteries
4. Decrease in suicide not linked to newer antidepressants
5. Autism: Lack of evidence for antidepressants
6. Certain Popular Antidepressants Linked to Cataracts in Seniors
7. Antidepressants in pregnancy increase risk of miscarriage
8. Antidepressants May Improve Heart Health
9. Antidepressants May Ease Damage From Stroke
10. Kids Suicide Risk Same for All Antidepressants
11. A new generation of rapid-acting antidepressants?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find 
(Date:4/29/2016)... City, Missouri (PRWEB) , ... April 29, 2016 , ... ... traditional crutches which put pressure on the armpits, the M+D Crutch evenly distributes body ... strain on their wrists and hands when using the crutches than with other crutches. ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... Canadian Celiac Association (CCA), is pleased to announce the launch of the ... nutritional articles, recipes, and more. The purpose of the GFCP Scoop ...
(Date:4/29/2016)... ... 29, 2016 , ... Dr. Robert Mondavi, one of the dentists in ... is a fast-growing field as more patients are discovering the many different ways they ... the options currently available to them and which ones might work for their smiles. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces ... the head and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ ... NASAL AIRWAY™ is a newly patented safety device secured by nasal surgeons onto ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... of a growth round of funding led by Eastside Partners, with participation from ... company’s rapidly growing customer base and accelerate its technology and product roadmap. ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology ... appointment of Dr. Alfredo Zurlo as Chief ... with many years clinical experience and a proven track ... role was at Mologen AG where he was Chief ... Dr. Zurlo held various positions at F Hoffmann La ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
Breaking Medicine Technology: